ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO289

Insights Into Current Practices and Unmet Needs Relating to CKD-Associated Pruritus: Results From a Canadian Nephrologist Survey

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Schwartz, Daniel, The University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada
  • Miciak, Gerald, Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada
  • Magnaye, Arthur, Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada

Chronic kidney disease-associated pruritus (CKD-aP) is a common condition in patients with CKD undergoing hemodialysis (HD). In this real-world study, Canadian nephrologists were surveyed to gain insight into current practices and unmet needs related to the treatment of CKD-aP.


Quantitative data regarding the perception of current treatment practices for CKD-aP were collected in November and December 2021 by a 20-minute survey completed by 62 nephrologists across Canada. Respondents’ level of agreement was assessed using a 7-point scale.


In current practice, the mean perceived prevalence of CKD-aP in HD patients was 30.5%. Of these, 33.6% and 18.3%, respectively, experience moderate or severe CKD-aP. CKD-aP was most frequently identified (75.8% of cases) through patients complaining of itch to the multidisciplinary health care team. In clinical practice 63% of respondents currently do not use formal scales to diagnose and assess CKD-aP. Treatments used for severe and moderate CKD-aP are shown in the table. Nephrologists used topical moisturizers / emollients (85%), oral antihistamines (14%), and gabapentinoids (2%) as first-line treatments. Nephrologists reported 42% of patients with severe CKD-aP and 41% with moderate CKD-aP do not respond to treatment. Most nephrologists (94%) agreed there is a need for new treatments specifically designed to address CKD-aP, 68% agreed they do not expect to resolve a patient's CKD-aP with currently available treatments, 89% agreed CKD-aP is challenging to treat, and 69% agreed there is a need for guidelines for the treatment of CKD-aP.


This real-world Canadian study of nephrologists showed that CKD-aP is challenging to treat and many patients do not respond to currently-available treatments. There is an urgent unmet need for new, more effective treatments and for guidelines to aid nephrologists in selecting therapy for their patients with CKD-aP.

Treatment Choices
TreatmentReported use in severe CKD-aP (%)
Reported use in moderate CKD-aP (%)
Topical moisturizers / emollients78
Oral antihistamines5837
Topical corticosteroids3520
UVB therapy228
Antidepressants / anxiolytics / sedatives145


  • Commercial Support